259 related articles for article (PubMed ID: 18563556)
1. Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors.
Bane AL; Pinnaduwage D; Colby S; Reedijk M; Egan SE; Bull SB; O'Malley FP; Andrulis IL
Breast Cancer Res Treat; 2009 Sep; 117(1):183-91. PubMed ID: 18563556
[TBL] [Abstract][Full Text] [Related]
2. Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes.
Stefansson OA; Jonasson JG; Johannsson OT; Olafsdottir K; Steinarsdottir M; Valgeirsdottir S; Eyfjord JE
Breast Cancer Res; 2009; 11(4):R47. PubMed ID: 19589159
[TBL] [Abstract][Full Text] [Related]
3. BRCA1 is a key regulator of breast differentiation through activation of Notch signalling with implications for anti-endocrine treatment of breast cancers.
Buckley NE; Nic An tSaoir CB; Blayney JK; Oram LC; Crawford NT; D'Costa ZC; Quinn JE; Kennedy RD; Harkin DP; Mullan PB
Nucleic Acids Res; 2013 Oct; 41(18):8601-14. PubMed ID: 23863842
[TBL] [Abstract][Full Text] [Related]
4. Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers.
Aaltonen K; Blomqvist C; Amini RM; Eerola H; Aittomäki K; Heikkilä P; Nevanlinna H
Clin Cancer Res; 2008 Apr; 14(7):1976-83. PubMed ID: 18381935
[TBL] [Abstract][Full Text] [Related]
5. miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers.
Vos S; Vesuna F; Raman V; van Diest PJ; van der Groep P
Oncotarget; 2015 Oct; 6(31):32115-37. PubMed ID: 26378051
[TBL] [Abstract][Full Text] [Related]
6. Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Antoniou AC; Spurdle AB; Sinilnikova OM; Healey S; Pooley KA; Schmutzler RK; Versmold B; Engel C; Meindl A; Arnold N; Hofmann W; Sutter C; Niederacher D; Deissler H; Caldes T; Kämpjärvi K; Nevanlinna H; Simard J; Beesley J; Chen X; ; Neuhausen SL; Rebbeck TR; Wagner T; Lynch HT; Isaacs C; Weitzel J; Ganz PA; Daly MB; Tomlinson G; Olopade OI; Blum JL; Couch FJ; Peterlongo P; Manoukian S; Barile M; Radice P; Szabo CI; Pereira LH; Greene MH; Rennert G; Lejbkowicz F; Barnett-Griness O; Andrulis IL; Ozcelik H; ; Gerdes AM; Caligo MA; Laitman Y; Kaufman B; Milgrom R; Friedman E; ; Domchek SM; Nathanson KL; Osorio A; Llort G; Milne RL; Benítez J; Hamann U; Hogervorst FB; Manders P; Ligtenberg MJ; van den Ouweland AM; ; Peock S; Cook M; Platte R; Evans DG; Eeles R; Pichert G; Chu C; Eccles D; Davidson R; Douglas F; ; Godwin AK; Barjhoux L; Mazoyer S; Sobol H; Bourdon V; Eisinger F; Chompret A; Capoulade C; Bressac-de Paillerets B; Lenoir GM; Gauthier-Villars M; Houdayer C; Stoppa-Lyonnet D; ; Chenevix-Trench G; Easton DF;
Am J Hum Genet; 2008 Apr; 82(4):937-48. PubMed ID: 18355772
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers.
Jazaeri AA; Yee CJ; Sotiriou C; Brantley KR; Boyd J; Liu ET
J Natl Cancer Inst; 2002 Jul; 94(13):990-1000. PubMed ID: 12096084
[TBL] [Abstract][Full Text] [Related]
8. EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry.
Bane AL; Mulligan AM; Pinnaduwage D; O'Malley FP; Andrulis IL
Breast Cancer Res Treat; 2011 Jun; 127(3):831-9. PubMed ID: 21327470
[TBL] [Abstract][Full Text] [Related]
9. Gene-expression profiles in hereditary breast cancer.
Hedenfalk I; Duggan D; Chen Y; Radmacher M; Bittner M; Simon R; Meltzer P; Gusterson B; Esteller M; Kallioniemi OP; Wilfond B; Borg A; Trent J; Raffeld M; Yakhini Z; Ben-Dor A; Dougherty E; Kononen J; Bubendorf L; Fehrle W; Pittaluga S; Gruvberger S; Loman N; Johannsson O; Olsson H; Sauter G
N Engl J Med; 2001 Feb; 344(8):539-48. PubMed ID: 11207349
[TBL] [Abstract][Full Text] [Related]
10. Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization.
Jönsson G; Naylor TL; Vallon-Christersson J; Staaf J; Huang J; Ward MR; Greshock JD; Luts L; Olsson H; Rahman N; Stratton M; Ringnér M; Borg A; Weber BL
Cancer Res; 2005 Sep; 65(17):7612-21. PubMed ID: 16140926
[TBL] [Abstract][Full Text] [Related]
11. Cross-species comparison of aCGH data from mouse and human BRCA1- and BRCA2-mutated breast cancers.
Holstege H; van Beers E; Velds A; Liu X; Joosse SA; Klarenbeek S; Schut E; Kerkhoven R; Klijn CN; Wessels LF; Nederlof PM; Jonkers J
BMC Cancer; 2010 Aug; 10():455. PubMed ID: 20735817
[TBL] [Abstract][Full Text] [Related]
12. Cyclin D1 is a direct target of JAG1-mediated Notch signaling in breast cancer.
Cohen B; Shimizu M; Izrailit J; Ng NF; Buchman Y; Pan JG; Dering J; Reedijk M
Breast Cancer Res Treat; 2010 Aug; 123(1):113-24. PubMed ID: 19915977
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers.
Palacios J; Honrado E; Osorio A; Cazorla A; Sarrió D; Barroso A; Rodríguez S; Cigudosa JC; Diez O; Alonso C; Lerma E; Sánchez L; Rivas C; Benítez J
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3606-14. PubMed ID: 14506147
[TBL] [Abstract][Full Text] [Related]
14. p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations.
Sensi E; Tancredi M; Aretini P; Cipollini G; Naccarato AG; Viacava P; Bevilacqua G; Caligo MA
Breast Cancer Res Treat; 2003 Nov; 82(1):1-9. PubMed ID: 14672397
[TBL] [Abstract][Full Text] [Related]
15. miRNA expression profiling of hereditary breast tumors from BRCA1- and BRCA2-germline mutation carriers in Brazil.
Pessôa-Pereira D; Evangelista AF; Causin RL; da Costa Vieira RA; Abrahão-Machado LF; Santana IVV; da Silva VD; de Souza KCB; de Oliveira-Silva RJ; Fernandes GC; Reis RM; Palmero EI; Marques MMC
BMC Cancer; 2020 Feb; 20(1):143. PubMed ID: 32087690
[TBL] [Abstract][Full Text] [Related]
16. Determination of molecular markers for BRCA1 and BRCA2 heterozygosity using gene expression profiling.
Salmon AY; Salmon-Divon M; Zahavi T; Barash Y; Levy-Drummer RS; Jacob-Hirsch J; Peretz T
Cancer Prev Res (Phila); 2013 Feb; 6(2):82-90. PubMed ID: 23341570
[TBL] [Abstract][Full Text] [Related]
17. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.
Collins LC; Martyniak A; Kandel MJ; Stadler ZK; Masciari S; Miron A; Richardson AL; Schnitt SJ; Garber JE
Am J Surg Pathol; 2009 Jul; 33(7):1093-7. PubMed ID: 19390427
[TBL] [Abstract][Full Text] [Related]
18. Altered gene expression in morphologically normal epithelial cells from heterozygous carriers of BRCA1 or BRCA2 mutations.
Bellacosa A; Godwin AK; Peri S; Devarajan K; Caretti E; Vanderveer L; Bove B; Slater C; Zhou Y; Daly M; Howard S; Campbell KS; Nicolas E; Yeung AT; Clapper ML; Crowell JA; Lynch HT; Ross E; Kopelovich L; Knudson AG
Cancer Prev Res (Phila); 2010 Jan; 3(1):48-61. PubMed ID: 20051372
[TBL] [Abstract][Full Text] [Related]
19. BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays.
Bane AL; Beck JC; Bleiweiss I; Buys SS; Catalano E; Daly MB; Giles G; Godwin AK; Hibshoosh H; Hopper JL; John EM; Layfield L; Longacre T; Miron A; Senie R; Southey MC; West DW; Whittemore AS; Wu H; Andrulis IL; O'Malley FP
Am J Surg Pathol; 2007 Jan; 31(1):121-8. PubMed ID: 17197928
[TBL] [Abstract][Full Text] [Related]
20. Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers.
Palacios J; Honrado E; Osorio A; Cazorla A; Sarrió D; Barroso A; Rodríguez S; Cigudosa JC; Diez O; Alonso C; Lerma E; Dopazo J; Rivas C; Benítez J
Breast Cancer Res Treat; 2005 Mar; 90(1):5-14. PubMed ID: 15770521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
